Glenmark Goa Plant Gets VAI Status from US FDA
Glenmark Pharmaceuticals has received Establishment Inspection Report (EIR) from US FDA for its Goa facility with VAI classification.
Voluntary Action Indicated | 23/09/2026 | By News Bureau
Aurobindo Pharma's Raleigh Plant Receives VAI Classification from US FDA
Aurobindo Pharma’s Raleigh plant receives Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (FDA), closing the inspection and allowing pending inhaler and dosage-form applications to progress.
Voluntary Action Indicated | 17/08/2026 | By News Bureau | 122
Zydus Lifesciences Reports 22 Percent Revenue Growth in Q1 FY27, Advances Innovation Pipeline
Zydus Lifesciences began FY27 with strong double-digit growth, driven by robust performance across India and international formulations, alongside continued progress in manufacturing quality and biosimilar innovation.
Voluntary Action Indicated | 12/08/2026 | By News Bureau
Torrent Pharmaceuticals Receives EIR from USFDA for Dahej Facility
The Dahej facility was placed under OAI by the USFDA based on the March 2019 Inspection outcome.
Voluntary Action Indicated | 25/08/2023 | By Manvi | 1870
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy